Pharma's New Marketing Realities
Executive Summary
With the traditional pharmaceutical commercial model in disarray, companies are looking for new approaches to maintaining their competitive position. They're talking about--and in some cases implementing--"new commercial models," which rely heavily on reorganizing sales and marketing organizations by region, decreasing emphasis on one-on-one physician relationships, and paying more attention to building business-to-business relationships with diverse stakeholders, notably payors-including public and private payors and employers--and patient advocacy groups.
You may also be interested in...
Novartis Reorganizes Its US Pharma Unit, Replacing CEO And Slashing 250 Jobs
The drug maker creates four business units, including primary care, which remains "critically important" to future growth.
Novartis Reorganizes Its US Pharma Unit, Replacing CEO And Slashing 250 Jobs
The drug maker creates four business units, including primary care, which remains "critically important" to future growth.
J&J Finds More Stakeholders Are Involved In Prescription Decisions And Thus Less Detailing Is Needed - And Eliminates 900 Pharma Sales Positions
Johnson & Johnson, like its competition, plans to respond to a changing health care environment by rolling out a new commercial model that reduces emphasis on detailing to doctors.